Key features and details | |
Cat. No. | MABL-1888 |
Name | Anti-HSP90 mAbs |
Clone No. | AFD- Myc123 (Efungumab; Mycograb) |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | therapeutic, ELISA |
Species Reactivity | Candida albicans |
Basic Information | |
Specificity | This antibody binds an epitope comprising amino acid sequence 'NKILKVIRKNIVKK' of heat shock protein 90 of Candida albicans. Homologous epitope have been identified in a number of fungal species like Candida parapsilosis, Torulopsis glabrata, Candida tropicalis, Candida krusei, and Aspergillus fumigatus. Hsp90 is a highly abundant and ubiquitous molecular chaperone which facilitates the maturation, structural maintenance and proper regulation of specific target proteins involved in cellular processes including cell cycle control, cell survival, hormone and other signaling pathways. It is important for the cell's response to stress and is a key player in maintaining cellular homeostasis. In recent years, hsp90 is being considered as an important therapeutic target for cancer and neurodegenerative diseases. |
Alternative Name | Heat shock protein 90 |
UniProt | P46598 |
Immunogen | The original antibody was recombinantly generated from the anti-HSP90 antibody cDNA isolated from blood lymphocytes of patients recently recovered from invasive candidiasis. |
Application Notes | This anti-fungal antibody has been used for the antibody based therapeutic treatment of systemic and invasive candidiasis (PMID: 11566001; 15040939). In an in vitro assays for efficacy assessment this antibody showed activity against a wide range of yeast species like Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata, and Candida parapsilosis. Murine kinetics showed that Mycograb at 2 mg/kg produced a maximum concentration of drug in serum of 4.7 ug/ml which produced significant improvement in murine candidiasis caused by each species. Complete resolution of infection was achieved for C.albicans, C. krusei, and C. glabrata only after combination with amphotericin B (PMID: 12821470). In a double-blind, randomized study comprising 139 patients it was reported that Mycograb plus lipid-associated amphotericin B produced significant clinical and culture-confirmed improvement in outcome for patients with invasive candidiasis (PMID: 16619152) |
Antibody First Published | Matthews et al. Antifungal antibodies: a new approach to the treatment of systemic candidiasis. Curr Opin Investig Drugs. 2001 Apr;2(4):472-6. PMID:11566001 |
Note on publication | This paper evaluates the use of antifungal antibodies in the antibody based therapeutic treatment of systemic candidiasis. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
